Seeking Alpha

Shares of Australian diagnostic firm Genetic Technologies (GENE +33%) are ripping today on the...

Shares of Australian diagnostic firm Genetic Technologies (GENE +33%) are ripping today on the back of a new bullish report issued by Australian investment bank Lodge Partner, starting the shares with a Buy and an aggressive $17 price target (that would make it a four-bagger from current levels). The firm says BREVAGen, GENE's key diagnostic product, is regaining momentum, noting that H2 sales rose 230% over H1, and it expects that trend to continue.
Comments (1)
  • Stratag
    , contributor
    Comments (5) | Send Message
     
    Looks like a wild swing will continue to $7.00 again. I am long here to $7.50 and expect a pull back.
    29 Aug 2012, 09:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs